Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
25.18
+1.05 (4.35%)
At close: Jun 26, 2026, 4:00 PM EDT
25.18
0.00 (-0.01%)
After-hours: Jun 26, 2026, 7:00 PM EDT
Company Description
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC.
The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Evommune, Inc.
| Country | United States |
| Founded | 2020 |
| IPO Date | Nov 6, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 48 |
| CEO | Luis Pena |
Contact Details
Address: 1891 Page Mill Road Palo Alto, California 94304 United States | |
| Phone | (925) 247-4481 |
| Website | evommune.com |
Stock Details
| Ticker Symbol | EVMN |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0002044725 |
| CUSIP Number | 30054Y107 |
| ISIN Number | US30054Y1073 |
| Employer ID | 85-0742575 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Luis C. Pena | Founder, President, Chief Executive Officer and Director |
| Kyle Carver CPA, M.B.A. | Chief Financial Officer |
| Gregory S. Moss Esq. | Chief Business and Legal Officer, Corporate Secretary and Chief Compliance Officer |
| Dr. Eugene Andrew Bauer M.D. | Co-Founder, Chief Medical Officer and Director |
| Dr. Jeegar Patel Ph.D. | Chief Scientific Officer |
| Janice Drew M.P.H. | Chief of Development Operations |
| Dr. Lou Sehl Ph.D. | Senior Vice President of Technical Operations |
| Dr. Daniel J. Burge M.d. | Senior Vice President of Clinical Development |
| J. Mark Jackson M.D. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 22, 2026 | 144 | Filing |
| Jun 2, 2026 | 144 | Filing |
| Jun 2, 2026 | 424B3 | Prospectus |
| Jun 2, 2026 | 8-K | Current Report |
| Jun 1, 2026 | 144 | Filing |
| Jun 1, 2026 | 144 | Filing |
| May 28, 2026 | 144 | Filing |
| May 28, 2026 | 144 | Filing |
| May 7, 2026 | 424B3 | Prospectus |
| May 7, 2026 | 10-Q | Quarterly Report |